HUTCHMED and AstraZeneca to Present Savolitinib Phase III NSCLC Data at ESMO
Question
HUTCHMED and AstraZeneca to Present Savolitinib Phase III NSCLC Data at ESMO
Direct answer
HUTCHMED and development partner AstraZeneca are set to unveil full Phase III clinical data for the savolitinib plus osimertinib combination in NSCLC at the ESMO Congress 2026 in Madrid. The presentations encompass the global SAFFRON study and China-focused SANOVO study, both of which reached statistically significant outcomes in targeting MET-amplified, EGFR-mutated non-small cell lung cancer. — bullish pressure on HCM.
- Original publisher
- Market Ontology
- Evidence through
- 2026-09-24
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “HUTCHMED and AstraZeneca to Present Savolitinib Phase III NSCLC Data at ESMO”, revision 1, evidence through 2026-09-24. https://marketontology.com/catalysts/2026-09-24/hutchmed-and-astrazeneca-to-present-savolitinib-phase-iii-nsclc-data-at-esmo-422ac5
HUTCHMED and AstraZeneca to Present Savolitinib Phase III NSCLC Data at ESMO
HUTCHMED and development partner AstraZeneca are set to unveil full Phase III clinical data for the savolitinib plus osimertinib combination in NSCLC at the ESMO Congress 2026 in Madrid. The presentations encompass the global SAFFRON study and China-focused SANOVO study, both of which reached statistically significant outcomes in targeting MET-amplified, EGFR-mutated non-small cell lung cancer. — bullish pressure on HCM.
HUTCHMED and development partner AstraZeneca are set to unveil full Phase III clinical data for the savolitinib plus osimertinib combination in NSCLC at the ESMO Congress 2026 in Madrid. The presentations encompass the global SAFFRON study and China-focused SANOVO study, both of which reached statistically significant outcomes in targeting MET-amplified, EGFR-mutated non-small cell lung cancer.
- SummaryHUTCHMED and development partner AstraZeneca are set to unveil full Phase III clinical data for the savolitinib plus osimertinib combination in NSCLC at the ESMO Congress 2026 in Madrid. The presentations encompass the global SAFFRON study and China-focused SANOVO study, both of which reached statistically significant outcomes in targeting MET-amplified, EGFR-mutated non-small cell lung cancer.
- HCMDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- HCM closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- HCM price vs. pre-event level
- HCM volume vs. 20-day average
HUTCHMED and AstraZeneca to Present Savolitinib Phase III NSCLC Data at ESMO
HUTCHMED and development partner AstraZeneca are set to unveil full Phase III clinical data for the savolitinib plus osimertinib combination in NSCLC at the ESMO Congress 2026 in Madrid. The presentations encompass the global SAFFRON study and China-focused SANOVO study, both of which reached statistically significant outcomes in targeting MET-amplified, EGFR-mutated non-small cell lung cancer. — bullish pressure on AZN.
HUTCHMED and development partner AstraZeneca are set to unveil full Phase III clinical data for the savolitinib plus osimertinib combination in NSCLC at the ESMO Congress 2026 in Madrid. The presentations encompass the global SAFFRON study and China-focused SANOVO study, both of which reached statistically significant outcomes in targeting MET-amplified, EGFR-mutated non-small cell lung cancer.
- SummaryHUTCHMED and development partner AstraZeneca are set to unveil full Phase III clinical data for the savolitinib plus osimertinib combination in NSCLC at the ESMO Congress 2026 in Madrid. The presentations encompass the global SAFFRON study and China-focused SANOVO study, both of which reached statistically significant outcomes in targeting MET-amplified, EGFR-mutated non-small cell lung cancer.
- AZNDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- AZN closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- AZN price vs. pre-event level
- AZN volume vs. 20-day average
What happened next
| Asset | Call | Base close | +1 day | +5 days | +20 days |
|---|---|---|---|---|---|
| HCM | Bullishagreed | 13.90 2026-09-24 | +0.29% | +4.82% | Pending |
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
No verifiable public source recorded for this card.
Related catalysts
- 2026-10-21HUTCHMED closed KRAS-EGFR therapy license to GSK outside ChinaGSK HCM
- 2026-10-21HUTCHMED closed a KRAS-EGFR license with GSK outside ChinaGSK HCM
- 2026-10-21HUTCHMED closes KRAS-EGFR license to GSK outside ChinaGSK HCM
- 2026-10-21HUTCHMED closes KRAS-EGFR conjugate license to GSK outside ChinaGSK HCM
- 2026-10-21HUTCHMED closes KRAS-EGFR license to GSK outside ChinaGSK HCM
- 2026-09-29AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung CancerAZN HCM+3.39%
- 2026-09-29AstraZeneca files US FDA NDA for savolitinib combo in MET-driven lung cancerAZN HCM+3.39%
- 2026-09-29AstraZeneca files US FDA NDA for savolitinib combo in MET-driven lung cancerAZN HCM+3.39%
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.